. 2020 May 18;37(6):2678–2695. doi: 10.1007/s12325-020-01378-y

Table 3.

Median survival estimates for the matching-adjusted second-line CELESTIAL population and the RESORCE population: weighted Kaplan-Meier estimates

		KM-derived estimate, months (median [95% CI])	p value
Overall survival
Active treatment	Cabozantinib (ESS = 187)	11.4 (8.9–17.0)	0.3474^a
Active treatment	Regorafenib (n = 379)	10.6 (9.1–12.1)	0.3474^a
Placebo	CELESTIAL (ESS = 81)	7.2 (6.1–10.8)	NE
Placebo	RESORCE (n = 194)	7.8 (6.3–8.8)	NE
Progression-free survival
Active treatment	Cabozantinib (ESS = 187)	5.6 (4.9–7.3)	0.0005^a
Active treatment	Regorafenib (n = 379)	3.1 (2.8–4.2)
Placebo	CELESTIAL (ESS = 81)	1.9 (1.9–2.1)	NE
Placebo	RESORCE (n = 194)	1.5 (1.4–1.6)

CI confidence interval, ESS effective sample size, KM Kaplan-Meier, NE not evaluated

^aLog-rank test